DE602004015811D1 - Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden - Google Patents

Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Info

Publication number
DE602004015811D1
DE602004015811D1 DE602004015811T DE602004015811T DE602004015811D1 DE 602004015811 D1 DE602004015811 D1 DE 602004015811D1 DE 602004015811 T DE602004015811 T DE 602004015811T DE 602004015811 T DE602004015811 T DE 602004015811T DE 602004015811 D1 DE602004015811 D1 DE 602004015811D1
Authority
DE
Germany
Prior art keywords
proliferation
inhibiting
platinum complexes
tumor cells
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004015811T
Other languages
German (de)
English (en)
Inventor
James Turkson
Richard Jove
Jay W Palmer
Heidi Kay
Hua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Publication of DE602004015811D1 publication Critical patent/DE602004015811D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004015811T 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden Expired - Lifetime DE602004015811D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48122603P 2003-08-13 2003-08-13
US51558003P 2003-10-30 2003-10-30
US51994303P 2003-11-14 2003-11-14
US52529503P 2003-11-25 2003-11-25
PCT/US2004/026392 WO2005023824A2 (en) 2003-08-13 2004-08-13 Methods for inhibiting tumor cell proliferation

Publications (1)

Publication Number Publication Date
DE602004015811D1 true DE602004015811D1 (de) 2008-09-25

Family

ID=34199238

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004015811T Expired - Lifetime DE602004015811D1 (de) 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DE602004024909T Expired - Lifetime DE602004024909D1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004024909T Expired - Lifetime DE602004024909D1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren

Country Status (8)

Country Link
US (6) US7566798B2 (enExample)
EP (2) EP1664070B1 (enExample)
JP (2) JP2007502301A (enExample)
AT (2) ATE453653T1 (enExample)
AU (3) AU2004270655B2 (enExample)
CA (2) CA2535584A1 (enExample)
DE (2) DE602004015811D1 (enExample)
WO (2) WO2005023824A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023824A2 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
EP1748772A2 (en) * 2004-04-09 2007-02-07 University Of South Florida Combination therapies for cancer and proliferative angiopathies
WO2007008247A2 (en) * 2004-11-10 2007-01-18 University Of South Florida Platinum complexes for targeted drug delivery
US7951374B2 (en) 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
DE102004060934A1 (de) * 2004-12-17 2006-06-29 Wacker Chemie Ag Vernetzbare Polyorganosiloxanmassen
AU2006266446B2 (en) * 2005-06-30 2011-03-10 Bionumerik Pharmaceuticals, Inc. Monoazole ligand platinum analogs
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
US20100247427A1 (en) * 2005-10-14 2010-09-30 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
US8895610B1 (en) * 2007-05-18 2014-11-25 Heldi Kay Platinum (IV) compounds targeting zinc finger domains
US8026382B2 (en) 2007-05-18 2011-09-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
CN101778857A (zh) * 2007-06-18 2010-07-14 普拉托技术（私有）公司 铂(iv)络合物
JP5688840B2 (ja) 2007-09-10 2015-03-25 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
US20100184854A1 (en) * 2008-12-12 2010-07-22 Platco Technologies (Proprietary) Limited Platinum (iv) complexes and methods of use thereof
DK3327148T3 (da) 2010-06-18 2021-04-12 Myriad Genetics Inc Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
US9512485B2 (en) 2010-08-24 2016-12-06 Dana-Farber Cancer Institute. Inc. Methods for predicting anti-cancer response
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
RU2491936C2 (ru) * 2011-07-11 2013-09-10 Борис Николаевич Анисимов Способ комплексного лечения больных паразитарными заболеваниями
DK2794907T4 (da) 2011-12-21 2023-02-27 Myriad Genetics Inc Fremgangsmåder og materialer til vurdering af tab af heterozygositet
EP2817630B1 (en) 2012-02-23 2018-07-11 Children's Medical Center Corporation Methods for predicting anti-cancer response
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
WO2014145428A2 (en) 2013-03-15 2014-09-18 Mcfarland Sherri Ann Metal-based coordination complexes as photodynamic compounds and their use
EP3693475A1 (en) 2013-04-05 2020-08-12 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
CN104230997B (zh) * 2013-06-13 2017-01-04 上海医药工业研究院 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用
US20160185808A1 (en) * 2013-07-25 2016-06-30 Srinivas Ganta Platinum derivatives for hydrophobic formulations
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
ES2800673T3 (es) 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
CA2988989A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
CA2988992A1 (en) 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN116854745A (zh) 2015-06-25 2023-10-10 新纳特产品公司 药物共晶组合物及其用途
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
AU2018372753B2 (en) 2017-11-21 2024-03-21 Medoncare Pharmaceutical Co., Ltd Combination product comprising dicycloplatin and preparation method and use thereof
CN112175014B (zh) * 2020-10-10 2021-08-20 中国药科大学 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
WO2024063828A1 (en) 2022-09-21 2024-03-28 Oracle International Corporation Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GR851932B (enExample) * 1984-08-14 1985-12-13 Engelhard Corp
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
JPH01156989A (ja) * 1987-09-25 1989-06-20 Ss Pharmaceut Co Ltd 新規白金錯体
ES2063119T3 (es) * 1988-02-02 1995-01-01 Johnson Matthey Inc Complejos de pt (iv).
JP3520367B2 (ja) * 1994-12-22 2004-04-19 独立行政法人産業技術総合研究所 白金ニトロアンミン系錯体の製造方法
DE69627641T2 (de) * 1995-02-28 2004-02-05 Kidani, Yoshinori, Fujisawa Platin(iv)-komplexe, verfahren zu ihrer herstellung und sie enthaltende carcinostatische mittel
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US5849790A (en) * 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
US6145688A (en) * 1996-07-17 2000-11-14 Smith; James C. Closure device for containers
US5977393A (en) 1997-11-21 1999-11-02 California Institute Of Technology Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts
KR100246722B1 (ko) * 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
EP1133317A1 (de) * 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
AU2002220979A1 (en) 2000-10-13 2002-04-22 Xigen Sa Intracellular delivery of biological effectors by novel transporter peptide sequences
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
WO2005023824A2 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
US20050288365A1 (en) 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
WO2007008247A2 (en) 2004-11-10 2007-01-18 University Of South Florida Platinum complexes for targeted drug delivery
WO2007006019A1 (en) 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression

Also Published As

Publication number Publication date
US7759510B2 (en) 2010-07-20
EP1675864A2 (en) 2006-07-05
US20100316704A1 (en) 2010-12-16
US7566798B2 (en) 2009-07-28
WO2005016946A3 (en) 2005-09-29
US7238372B2 (en) 2007-07-03
AU2004264421B2 (en) 2011-02-24
EP1675864B1 (en) 2009-12-30
WO2005023824A2 (en) 2005-03-17
US7763585B2 (en) 2010-07-27
AU2004270655B2 (en) 2011-03-24
AU2004264421A1 (en) 2005-02-24
ATE404574T1 (de) 2008-08-15
US20080187992A1 (en) 2008-08-07
JP2007502301A (ja) 2007-02-08
US20050080131A1 (en) 2005-04-14
US8247445B2 (en) 2012-08-21
US20050074502A1 (en) 2005-04-07
ATE453653T1 (de) 2010-01-15
US20100310645A1 (en) 2010-12-09
AU2011202386A1 (en) 2011-06-09
WO2005016946A2 (en) 2005-02-24
EP1664070B1 (en) 2008-08-13
AU2004270655A1 (en) 2005-03-17
CA2535584A1 (en) 2005-02-24
US20090285884A1 (en) 2009-11-19
DE602004024909D1 (de) 2010-02-11
CA2535762A1 (en) 2005-03-17
WO2005023824A3 (en) 2005-06-09
US8598230B2 (en) 2013-12-03
JP2007502777A (ja) 2007-02-15
EP1664070A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE447965T1 (de) Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ATE554087T1 (de) Neue kinaseinhibitoren
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
DE602005021684D1 (de) Verfahren zur herstellung von pimecrolimus
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
ATE431426T1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
DE602005015174D1 (de) Verfahren zur herstellung von montelukast-natrium
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
DK1773420T3 (da) Anvendelse af gingivale fibroblaster til vaskulær celleterapi
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
TW200716132A (en) Novel chemical compounds
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2005070042A3 (en) Novel chemical compounds
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition